JP2021184731A5 - - Google Patents

Download PDF

Info

Publication number
JP2021184731A5
JP2021184731A5 JP2021128846A JP2021128846A JP2021184731A5 JP 2021184731 A5 JP2021184731 A5 JP 2021184731A5 JP 2021128846 A JP2021128846 A JP 2021128846A JP 2021128846 A JP2021128846 A JP 2021128846A JP 2021184731 A5 JP2021184731 A5 JP 2021184731A5
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
binding
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021128846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021184731A (ja
Filing date
Publication date
Priority claimed from EP15305078.6A external-priority patent/EP2955196A1/en
Application filed filed Critical
Publication of JP2021184731A publication Critical patent/JP2021184731A/ja
Publication of JP2021184731A5 publication Critical patent/JP2021184731A5/ja
Pending legal-status Critical Current

Links

JP2021128846A 2014-06-10 2021-08-05 Cd127に対する抗体 Pending JP2021184731A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462010117P 2014-06-10 2014-06-10
US62/010,117 2014-06-10
EP15305078.6 2015-01-23
EP15305078.6A EP2955196A1 (en) 2014-06-10 2015-01-23 Antibodies directed against CD127
JP2017517406A JP7324565B2 (ja) 2014-06-10 2015-06-10 Cd127に対する抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017517406A Division JP7324565B2 (ja) 2014-06-10 2015-06-10 Cd127に対する抗体

Publications (2)

Publication Number Publication Date
JP2021184731A JP2021184731A (ja) 2021-12-09
JP2021184731A5 true JP2021184731A5 (Direct) 2022-03-03

Family

ID=52434718

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017517406A Active JP7324565B2 (ja) 2014-06-10 2015-06-10 Cd127に対する抗体
JP2021128846A Pending JP2021184731A (ja) 2014-06-10 2021-08-05 Cd127に対する抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017517406A Active JP7324565B2 (ja) 2014-06-10 2015-06-10 Cd127に対する抗体

Country Status (26)

Country Link
US (3) US10428152B2 (Direct)
EP (2) EP2955196A1 (Direct)
JP (2) JP7324565B2 (Direct)
KR (1) KR102612930B1 (Direct)
CN (1) CN106715471B (Direct)
AP (1) AP2016009599A0 (Direct)
AU (1) AU2015273532C1 (Direct)
BR (1) BR112016028755B1 (Direct)
CA (1) CA2950823A1 (Direct)
CL (1) CL2016003172A1 (Direct)
CR (1) CR20160576A (Direct)
EA (1) EA039303B1 (Direct)
HK (1) HK1231487A1 (Direct)
IL (1) IL249449B (Direct)
MA (1) MA40202A (Direct)
MX (1) MX376066B (Direct)
MY (1) MY190889A (Direct)
NZ (1) NZ726932A (Direct)
PE (1) PE20170324A1 (Direct)
PH (1) PH12016502445A1 (Direct)
RU (1) RU2734076C2 (Direct)
SA (1) SA516380455B1 (Direct)
SG (1) SG11201610036PA (Direct)
TN (1) TN2016000528A1 (Direct)
UA (1) UA125366C2 (Direct)
WO (1) WO2015189302A1 (Direct)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
EP3277713B1 (en) 2015-03-31 2025-09-10 Sorriso Pharmaceuticals, Inc. Polypeptides
CA2981098A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
EP3405491A1 (en) 2016-01-21 2018-11-28 VHsquared Limited Polypeptides
BR112018067479A2 (pt) * 2016-02-29 2019-01-15 Ose Immunotherapeutics anticorpo, fragmento de ligação ao antígeno de um anticorpo, molécula quimérica, receptor de antígeno quimérico, polinucleotídeo, célula, métodos para preparação de receptor de antígeno quimérico, para fabricação de um anticorpo e para determinação da presença de células cd127+, composição farmacêutica, meio terapêutico de combinação, método de diagnóstico, e, uso de um anticorpo anti-cd127 ou um fragmento de ligação ao antígeno do mesmo
CA3042582C (en) * 2016-12-09 2023-05-23 Ose Immunotherapeutics Antibodies and polypeptides directed against cd127
US12258577B2 (en) 2017-08-29 2025-03-25 Ose Immunotherapeutics Method effector cells using anti-CD127 antibodies for applications in cell therapy
CN110117325B (zh) * 2018-03-09 2023-06-20 重庆市畜牧科学院 一种猪cd127多肽及其编码基因和应用
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
JP7702363B2 (ja) 2019-06-21 2025-07-03 ソリッソ ファーマシューティカルズ,インク. 組成物
WO2020254826A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
CN114466864B (zh) 2019-06-21 2024-12-27 索瑞索制药公司 多肽
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
CA3181394A1 (en) * 2020-04-27 2021-11-04 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting cd127 and use thereof
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
JP2025518164A (ja) 2022-05-30 2025-06-12 オセ イムノセラピューティクス Il7rモジュレーター活性のバイオマーカー
CN115925955B (zh) * 2022-12-30 2025-09-26 浙江正熙生物技术有限公司 一种抗cd127抗体及其制备方法和应用
CN121002069A (zh) 2023-01-06 2025-11-21 泰温治疗私人有限公司 抗原结合分子
EP4455308A1 (en) 2023-04-24 2024-10-30 Les Laboratoires Servier Il-7r gene signatures
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025089399A1 (ja) * 2023-10-26 2025-05-01 国立研究開発法人国立がん研究センター インターロイキン7受容体(il-7r)に対する抗体および当該抗体を含む抗体薬物コンジュゲート(adc)
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN118638236B (zh) * 2024-07-09 2025-03-14 武汉爱博泰克生物科技有限公司 抗人cd127蛋白的抗体、抗体偶联物及其应用
WO2026022216A1 (en) 2024-07-23 2026-01-29 Ose Immunotherapeutics Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US9012134B2 (en) 2006-05-31 2015-04-21 The Regents Of The University Of California CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ Tregs
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
TW201018482A (en) * 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
WO2010085643A1 (en) 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
WO2011094259A2 (en) * 2010-01-28 2011-08-04 Glaxo Group Limited Cd127 binding proteins
US8298535B2 (en) 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
BR112018067479A2 (pt) 2016-02-29 2019-01-15 Ose Immunotherapeutics anticorpo, fragmento de ligação ao antígeno de um anticorpo, molécula quimérica, receptor de antígeno quimérico, polinucleotídeo, célula, métodos para preparação de receptor de antígeno quimérico, para fabricação de um anticorpo e para determinação da presença de células cd127+, composição farmacêutica, meio terapêutico de combinação, método de diagnóstico, e, uso de um anticorpo anti-cd127 ou um fragmento de ligação ao antígeno do mesmo

Similar Documents

Publication Publication Date Title
JP2021184731A5 (Direct)
KR102821932B1 (ko) 항-ccr8 항체 및 이의 용도
JP7325936B2 (ja) 改善された貯蔵及び投与のための、二重特異性抗体構築物を含む医薬組成物
JP2017522903A5 (Direct)
JP7011574B2 (ja) Flt3及びcd3に対する抗体構築物
JP6879998B2 (ja) Cd70及びcd3に対する抗体構築物
JP6726168B2 (ja) Cdh19およびcd3に対する抗体コンストラクト
JP6907124B2 (ja) Cdh3及びcd3に対する二重特異性抗体構築物
JP6305919B2 (ja) Mcamアンタゴニスト及び治療の方法
RU2016151265A (ru) Антитела, направленные на cd127
KR20240118898A (ko) Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
SA515360253B1 (ar) أجسام مضادة مُميزة لألفا سينوكلين
TW201708261A (zh) Dll3及cd3抗體構築體
KR20160065981A (ko) 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
CN110396129A (zh) 人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用
AU2014305658A1 (en) An antibody therapy for amyloid beta disease
CA2986210C (en) Novel anti-human ngf antibody fab fragment
TW202306990A (zh) 特異性結合rankl和ngf的抗原結合分子及其醫藥用途
US11702470B2 (en) Use of CXCL13 binding molecules to promote peripheral nerve regeneration
JP2024526154A (ja) フィブロネクチン-インテグリン相互作用及びシグナル伝達を検出及び調節するための組成物及び方法
WO2025171411A1 (en) Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
KR20230144870A (ko) Mincle 억제제를 포함하는 신경병성 통증 치료용 약학 조성물
EA046884B1 (ru) Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение